logo

Clearside Biomedical, Inc. (CLSD)



Trade CLSD now with
  Date
  Headline
1/12/2021 7:28:03 AM Clearside Biomedical Says First Patients Enrolled In Phase 1/2a Clinical Trial Of CLS-AX
1/6/2021 7:11:02 AM Clearside Biomedical Enters Deal For Purchase And Sale Of 4.21 Mln Shares At $2.851/Shr Priced At-the-market
1/28/2020 7:20:14 AM Bausch Health And Clearside Biomedical Announce Publication Of PIVOTAL Phase 3 Data ON XIPERETM In Ophthalmology
10/23/2019 7:41:52 AM Bausch Health Buys License For Commercialization Of XIPERE In The United States And Canada
8/22/2019 7:10:29 AM Clearside Expects To Receive CRL From FDA For XIPERE On Or Before Oct 19; Plans To Re-submit NDA In Q1 2020
7/29/2019 7:18:50 AM Wedbush Reiterates Clearside Biomedical, Inc. (CLSD) At Outperform With $4 Price Target
7/10/2019 6:49:54 AM Wedbush Reiterates Clearside Biomedical, Inc. (CLSD) At Outperform With $4 Price Target
7/9/2019 7:12:33 AM Clearside Biomedical Enters Worldwide Licensing Agreement With Aura Biosciences
5/9/2019 7:50:06 AM Wedbush Is Raising Clearside Biomedical, Inc. (CLSD) FY20 Rev. Estimate To 7.6 M From 7.4 M
5/9/2019 7:49:50 AM Wedbush Is Raising Clearside Biomedical, Inc. (CLSD) Q3 20 Rev. Estimate To 2.1 M From 2.0 M
5/9/2019 7:49:36 AM Wedbush Is Increasing Clearside Biomedical, Inc. (CLSD) Q2 20 Rev. Estimate To 1.6 M From 1.5 M